Myeloproliferative neoplasms: from origins to outcomes.

Abstract excerpt

Substantial progress has been made in our understanding of the pathogenetic basis of myeloproliferative neoplasms. The discovery of mutations in JAK2 over a decade ago heralded a new age for patient care as a consequence of improved diagnosis and the development of therapeutic JAK inhibitors. The more recent identification of mutations in calreticulin brought with it a sense of completeness, with most patients...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Transformation, Neoplastic
• Share to Clonal Evolution
• Share to Disease Progression